These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 37588995)

  • 41. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genome-wide Exploration of a Pyroptosis-Related Long Non-Coding RNA Signature Associated With the Prognosis and Immune Response in Patients With Bladder Cancer.
    Gao X; Cai J
    Front Genet; 2022; 13():865204. PubMed ID: 35571063
    [No Abstract]   [Full Text] [Related]  

  • 43. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
    Li R; Zhao W; Liang R; Jin C; Xiong H
    Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
    [No Abstract]   [Full Text] [Related]  

  • 45. A risk model based on pyroptosis subtypes predicts tumor immune microenvironment and guides chemotherapy and immunotherapy in bladder cancer.
    Wu T; Li S; Yu C; Wu Y; Long H
    Sci Rep; 2022 Dec; 12(1):21467. PubMed ID: 36509838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A comprehensive analysis of immunogenic cell death and its key gene HSP90AA1 in bladder cancer.
    Song Q; Zhou Z; Bai J; Liu N
    Clin Transl Oncol; 2023 Aug; 25(8):2587-2606. PubMed ID: 37000291
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 49. Generalized machine learning based on multi-omics data to profile the effect of ferroptosis pathway on prognosis and immunotherapy response in patients with bladder cancer.
    Liu X; Qiu Z; Zhang X; Su Z; Yi R; Zou D; Xie C; Jin N; Long W; Liu X
    Environ Toxicol; 2024 Feb; 39(2):680-694. PubMed ID: 37647346
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Integrated analysis of single-cell and bulk RNA-sequencing identifies a signature based on T-cell marker genes to predict prognosis and immunotherapy response in bladder cancer.
    Shi X; Dong A; Yang Y; Zheng G; Wang N; Yang C; Wang Y; Lu J; Jia X
    J Cancer Res Clin Oncol; 2023 Sep; 149(12):9733-9746. PubMed ID: 37244876
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Identification of a cancer-associated fibroblast signature for predicting prognosis and immunotherapeutic responses in bladder urothelial carcinoma.
    Gu Y; Zhuo H
    Aging Male; 2023 Dec; 26(1):2233609. PubMed ID: 37428096
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    Tao Y; Li X; Zhang Y; He L; Lu Q; Wang Y; Pan L; Wang Z; Feng C; Xie Y; Lai Z; Li T; Tang Z; Wang Q; Wang X
    Front Genet; 2022; 13():1057302. PubMed ID: 36568387
    [No Abstract]   [Full Text] [Related]  

  • 53. Immune landscape of distinct subtypes in urothelial carcinoma based on immune gene profile.
    Peng M
    Front Immunol; 2022; 13():970885. PubMed ID: 36003383
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Predicting Prognosis and Distinguishing Cold and Hot Tumors in Bladder Urothelial Carcinoma Based on Necroptosis-Associated lncRNAs.
    Liu D; Xu S; Chang T; Ma S; Wang K; Sun G; Chen S; Xu Y; Zhang H
    Front Immunol; 2022; 13():916800. PubMed ID: 35860239
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer.
    Zhang L; Li L; Zhan Y; Wang J; Zhu Z; Zhang X
    Front Oncol; 2020; 10():542140. PubMed ID: 33552945
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Uncovering the potential functions of lymph node metastasis-associated aberrant methylation differentially expressed genes and their association with the immune infiltration and prognosis in bladder urothelial carcinoma.
    Gao W; Zhang J; Tian T; Fu Z; Bai L; Yang Y; Wu Q; Wang W; Guo Y
    PeerJ; 2023; 11():e15284. PubMed ID: 37123010
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A novel platelet risk score for stratifing the tumor immunophenotypes, treatment responses and prognosis in bladder carcinoma: results from real-world cohorts.
    Deng D; Li X; Qi T; Dai Y; Liu N; Li H
    Front Pharmacol; 2023; 14():1187700. PubMed ID: 37214475
    [No Abstract]   [Full Text] [Related]  

  • 58. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognosis Risk Model Based on Necroptosis-Related Signature for Bladder Cancer.
    Chen Z; Cao R; Wang R; Wang Y; Shang D; Tian Y
    Genes (Basel); 2022 Nov; 13(11):. PubMed ID: 36421795
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
    Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
    Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.